Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC30 in obesity and overweight with comorbidities
NCT07002905Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ASC30 in obesity, sponsored by Ascletis Pharma Inc.. Started Jul 2025; status: completed.
02
Drugs
ASC30
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07002905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002905.